Companies in #Hematology

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.

BeOne Medicines is a global oncology company that discovers and develops innovative medicines intended to improve the lives of patients worldwide. The company markets BRUKINSA (zanubrutinib), a BTK inhibitor approved for B-cell malignancies.

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Disc Medicine is a clinical-stage biopharmaceutical company developing novel hematology therapeutics for patients with serious and rare blood diseases. The company's pipeline includes bitopertin (a glycine transport-1 inhibitor) for erythropoietic protoporphyria (EPP) and other hematologic disorders.

Swiss-headquartered plasma products company specializing in coagulation factor therapies (wilate, Nuwiq) for hemophilia and von Willebrand disease, with operations across 40+ countries.

Orca Bio is a clinical-stage cell therapy company developing high-precision, allogeneic cell therapies for cancer and autoimmune diseases.